Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Krystal Biotech, Inc. Common Stock

KRYS

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Last trade $296.32
Day change -$1.58 (-0.53%)
Day range $295.44 – $300.00
Volume 51,185
Market cap $8.83B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$8.83B
Price / earnings
39.21×
Price / book
6.15×
Price / sales
18.78×
EV / sales
17.8×
EV / EBITDA
35.83×

Profitability

Earnings per share
$7.60
Return on assets
14.2%
Return on equity
15.68%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.89×
Quick ratio
7.53×
Cash ratio
3.26×

Cash flow

Price / cash flow
27.25×
Price / free cash flow
28.47×
Free cash flow
$310.08M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for KRYS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$127.34M$119.22M$116.36M$107.11M$97.8M$96.04M$88.18M$91.14M
Cost of revenue$7.56M$6.44M$6.32M$6.59M$4.26M$7.17M$5.03M$4.95M
Gross profit$119.79M$112.79M$110.03M$100.51M$93.54M$88.88M$83.16M$86.19M
Selling, general and administrative$33.75M$39.85M$41.01M$41.45M$37.58M$35.07M$32.65M$31.29M
Research and development$14.89M$14.52M$15.33M$14.79M$14.59M$14.41M$14.26M$13.53M
Total operating expenses$48.64M$54.37M$56.35M$56.24M$52.16M$49.48M$46.9M$44.82M
Operating income$71.15M$58.42M$53.69M$44.27M$41.37M$39.4M$36.25M$41.38M
Interest expense$0$7.66M$7.75M$0$0$7.38M$7.35M$0
Income before taxes$80.15M$66.08M$61.44M$51.13M$47.97M$46.78M$43.6M$48.61M
Income taxes$17.08M$11.31M$5.51M-$269K-$31.4M$8.44M$7.86M$3.13M
Net income$63.07M$54.77M$55.93M$51.4M$79.37M$38.33M$35.73M$45.48M
Net income attributable to common shareholders$63.07M$54.77M$55.93M$51.4M$79.37M$38.33M$35.73M$45.48M
EBITDA$72.62M$59.77M$55.21M$45.83M$42.78M$40.75M$37.66M$42.74M
Basic earnings per share$2.13$1.85$1.91$1.77$2.74$1.33$1.24$1.58
Diluted earnings per share$2.05$1.79$1.83$1.69$2.66$1.29$1.20$1.51

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

Krystal Biotech reported Q3 2026 earnings of $2.05 per share, beating consensus estimates of $1.84 per share, with revenues of $127.34 million exceeding expectations by 2.16%. However, despite the earnings beat and 34.8% year-to-date stock gain, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends, suggesting near-term underperformance relative to the market.

Zacks Investment Research

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

Krystal Biotech is expected to report a 30.8% year-over-year decline in earnings per share to $1.84 for Q3 2026, despite revenues rising 27.5% to $124.65 million. With a Zacks Rank of #5 (Strong Sell) and a modest positive Earnings ESP of +1.50%, the stock is not considered a compelling earnings-beat candidate. The company has historically beaten consensus estimates in four of the last four quarters.

Zacks Investment Research

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Krystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development.

GlobeNewswire Inc.

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

Krystal Biotech announced its participation in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will participate in a fireside chat at 3:55 pm ET and host investor meetings. The company reported strong Q2 2026 results with $119.2 million in VYJUVEK global revenue and $965.9 million in cumulative revenue since launch, with plans for European expansions and multiple clinical data readouts expected in the second half of 2026.

Zacks Investment Research

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

Krystal Biotech shares have gained 12% since its last earnings report, outperforming the S&P 500. The company beat Q2 2026 earnings estimates with EPS of $1.79 vs. consensus of $1.70, and revenues of $119.2 million from Vyjuvek sales grew 24% year-over-year. Despite upward estimate revisions, the stock holds a Zacks Rank #3 (Hold) with an overall VGM Score of D, suggesting in-line returns ahead.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.